AZD0530 to Treat Recurrent Stage IIIB/IV NSCLC Previously Treated With Combination Chemotherapy

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT00638937
First received: March 18, 2008
Last updated: June 22, 2015
Last verified: October 2013

March 18, 2008
June 22, 2015
February 2008
June 2013   (final data collection date for primary outcome measure)
Rate of Disease Control (Freedom From Disease Progression) [ Time Frame: 112 days ] [ Designated as safety issue: No ]

Lack of disease progression, a combined rate of objective complete (disapprearance of all target lesions) and partial responses (>= 30% decrease in sum of longest diameter of target lesions) and stable disease as determined by Response Evaluation Criteria in Solid Tumours (RECIST 1.0) for at least 4 cycles (16 weeks) of therapy.

Standard descriptive statistics, such as the mean, median, range and proportion, will be used to summarize the patient sample and to estimate parameters of interest. Ninety-five percent confidence intervals will be provided for estimates of interest where possible.

Rate of disease control (freedom from disease progression) after 4 courses of treatment [ Designated as safety issue: No ]
Complete list of historical versions of study NCT00638937 on ClinicalTrials.gov Archive Site
  • Objective Response Rate (Complete and Partial Response) [ Time Frame: From the start of the treatment until the criteria for response are met ] [ Designated as safety issue: No ]

    Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions Overall Response (OR) = CR + PR

    Standard descriptive statistics, such as the mean, median, range and proportion, will be used to summarize the patient sample and to estimate parameters of interest. Ninety-five percent confidence intervals will be provided for estimates of interest where possible.

  • Stable Disease Rate [ Time Frame: From the start of the treatment until the criteria for progression are met, assessed up to 1 year ] [ Designated as safety issue: No ]

    Stabilization of disease for atleast 4 cycles, leading to disease control

    Standard descriptive statistics, such as the mean, median, range and proportion, will be used to summarize the patient sample and to estimate parameters of interest. Ninety-five percent confidence intervals will be provided for estimates of interest where possible.

  • Duration of Response or Stable Disease [ Time Frame: From first response until the criteria for progression are met, assessed up to 1 year ] [ Designated as safety issue: No ]
    Standard descriptive statistics, such as the mean, median, range and proportion, will be used to summarize the patient sample and to estimate parameters of interest. Ninety-five percent confidence intervals will be provided for estimates of interest where possible.
  • Median Progression-free Survival [ Time Frame: From the date of study enrollment to the time the criteria for disease progression are met, death or last contact, or the last tumor assessment before the initiation of further anticancer therapy, assessed up to 1 year ] [ Designated as safety issue: No ]
    The Kaplan-Meier method will be used.
  • Progression-free Survival [ Time Frame: 6 months ] [ Designated as safety issue: No ]

    Progression free survival (PFS) is defined as the time from randomization to the date of first documented disease progression or death from any cause

    The Kaplan-Meier method will be used.

  • Median Overall Survival [ Time Frame: Up to 1 year ] [ Designated as safety issue: No ]
    The Kaplan-Meier method will be used.
  • Overall Survival [ Time Frame: 1 year ] [ Designated as safety issue: No ]

    One year overall survival rate

    The Kaplan-Meier method will be used.

  • Objective response rate (complete and partial response) [ Designated as safety issue: No ]
  • Stable disease rate [ Designated as safety issue: No ]
  • Duration of response or stable disease [ Designated as safety issue: No ]
  • Progression-free, median, and overall survival at 6 months [ Designated as safety issue: No ]
  • Safety and tolerability [ Designated as safety issue: Yes ]
  • Correlation of clinical outcomes with correlative studies performed on blood and tumor biopsy samples [ Designated as safety issue: No ]
Not Provided
Not Provided
 
AZD0530 to Treat Recurrent Stage IIIB/IV NSCLC Previously Treated With Combination Chemotherapy
A Phase 2 Study of AZD0530 in Patients With Advanced, Recurrent Non-Small Cell Lung Cancer Who Have Previously Received Platinum-Based Combination Chemotherapy

This phase II trial is studying how well saracatinib works in treating patients with recurrent, stage IIIB or stage IV non-small cell lung cancer previously treated with combination chemotherapy that included cisplatin or carboplatin. Saracatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

PRIMARY OBJECTIVES:

I. Assess the rate of disease control (i.e., lack of disease progression, a combined rate of objective complete and partial response, and stable disease) for at least 4 cycles of therapy in patients with AZD0530 (saracatinib) in patients with advanced non-small cell lung cancer that had previously been treated with platinum-based combination chemotherapy.

SECONDARY OBJECTIVES:

I. To assess the objective response rate (complete and partial response), stable disease rate, duration of response or stable disease, progression-free, median and 6 month overall survival rates, safety and tolerability of this treatment.

TERTIARY OBJECTIVES:

I. To evaluate potential predictive markers by assessing pretreatment intratumoral levels of src, Y419 phospho-src (P-Src) and c-terminal src kinase (Csk) in archival tumor biopsies.

OUTLINE: This is a multicenter study.

Patients receive saracatinib orally (PO) once daily (QD) on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Tumor tissue samples are collected at baseline and at 2 weeks after beginning treatment and are analyzed for c-Src protein expression and activity by immunofluorescence staining. P-glycoprotein levels and phosphorylation of focal adhesion kinase (FAK), paxillin, caveolin, and Stat-3 are also measured using tumor tissue samples. Blood samples are also used to measure levels of vascular endothelial growth factor (VEGF) by enzyme-linked immunosorbent assay (ELISA).

After completion of study treatment, patients are followed every 4 weeks.

Interventional
Phase 2
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Recurrent Non-small Cell Lung Cancer
  • Stage IIIB Non-small Cell Lung Cancer
  • Stage IV Non-small Cell Lung Cancer
Drug: saracatinib
Given PO
Other Name: AZD0530
Experimental: Treatment (saracatinib)
Patients receive saracatinib PO, at a dose of 175 mg QD on days 1-28. Courses repeat every 28 days in the absence of unacceptable toxicity or disease progression
Intervention: Drug: saracatinib
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
37
June 2013
June 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Recurrent/metastatic/locally advanced unresectable, histologically or cytologically confirmed NSCLC
  • Measurable disease defined (RECIST) as at least 1 lesion measured in at least 1 dimension (longest diameter) as >20mm with conventional techniques or >10mm with spiral CT scan
  • Previously treated with firstline platinum-based systemic chemotherapy for advanced disease AND had at least disease stabilization as best response to firstline therapy

    • <=1 line of prior therapy
    • Not have had prior treatment with EGFR Tyrosine kinase inhibitor
    • Completed chemotherapy/surgery/radiotherapy 4 weeks before study entry and must have recovered from toxic effects of prior therapy
    • Had >40% of their bone marrow radiated and must have either measurable disease outside field/documented progression post radiation therapy
  • Life expectancy >3 months
  • ECOG performance status =<2 OR Karnofsky >=60%
  • Leukocytes >=3x10^9/L
  • Absolute neutrophil count >=1.5x10^9/L
  • Platelet count >=10x10^9/L
  • Hemoglobin >9g/dL (may be transfused to meet this)
  • Total bilirubin =<1.5 times institutional ULN (IULN)
  • AST/ALT =<2.5xIULN (=<5 times ULN in the presence of liver metastases)
  • Creatinine =<1.5xIULN OR creatinine clearance >=50 mL/min/1.73m^2
  • Urine protein creatinine ratio =<1.0 OR urine protein >1.0, 24 hour urine for protein should be <1000mg
  • Women of childbearing potential/men must use adequate contraception (hormonal/barrier method of birth control; abstinence) prior to study entry, for duration of study participation, and for 8 weeks following cessation of study therapy
  • Ability to understand/willingness to sign written informed consent

Exclusion Criteria:

  • Chemotherapy/radiotherapy within 4 weeks (6 weeks for nitrosoureas/mitomycin C) prior to study entry/not recovered from AEs due to agents administered > than 4 weeks earlier
  • No CYP3A4-active agents permitted during protocol treatment. Patients requiring treatment with these agents are not eligible; prohibited drugs should be discontinued 7 days before first dose of AZD0530 and for 7 days after discontinuation of AZD0530
  • Cannot receive other investigational agents
  • History of allergic reactions attributed to compounds of similar chemical/biologic composition to AZD0530
  • QTc prolongation (i.e.QTc interval >=460 msec)/other significant ECG abnormalities
  • Poorly controlled hypertension (i.e.systolic BP of 140 mmHg or higher, diastolic BP of 90mm Hg or higher)
  • Any condition impairing ability to swallow AZD0530 tablets
  • Treated brain metastases which are clinically and radiologically stable are permitted; patients requiring steroids/with neurological symptoms should be excluded because of poor prognosis/often develop progressive neurologic dysfunction
  • Intercurrent cardiac dysfunction including but not limited to symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia are excluded as are those with ischemic heart disease history including myocardial infarction
  • Uncontrolled intercurrent illness including but not limited to ongoing/active infection or psychiatric illness/social situations that would limit compliance with study requirements
  • Pregnant women excluded because AZD0530 has potential teratogenic/abortifacient effects; because unknown but potential risks for AEs in nursing infants secondary to treatment of mother with AZD0530, breastfeeding should be discontinued if mother is treated with AZD0530
  • HIV-positive patients on combination antiretroviral therapy are ineligible because potential for PK interactions with AZD0530; these patients have increased risk of lethal infections when treated with marrow-suppressive therapy; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Canada
 
NCT00638937
NCI-2009-01053, NCI-2009-01053, PMH-PHLO-053, CDR0000587610, PHL-053, 7555, N01CM00032, N01CM62203
Yes
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Not Provided
Principal Investigator: Scott Laurie University Health Network-Princess Margaret Hospital
National Cancer Institute (NCI)
October 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP